Oncotarget

Research Papers:

Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma

Shujuan Zhou _, Linglong Xu, Yongyong Ma, Liyuan Tang, Yu Zhang, Yifen Shi, Lan Sun, Yi Chen, Bin Liang, Yuhong Zhou, Kang Yu and Jianping Shen

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:19556-19565. https://doi.org/10.18632/oncotarget.14700

Metrics: PDF 1070 views  |   HTML 1827 views  |   ?  


Abstract

Shujuan Zhou1, Linglong Xu1, Yongyong Ma2, Liyuan Tang2, Yu Zhang2, Yifen Shi2, Lan Sun2, Yi Chen2, Bin Liang2, Yuhong Zhou3, Kang Yu2, Jianping Shen3

1The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China

2Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China

3Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China

Correspondence to:

Yuhong Zhou, email: [email protected]

Kang Yu, email: [email protected]

Jianping Shen, email: [email protected]

Keywords: lymphocyte, monocyte, prognosis, diffuse large B-cell lymphoma

Received: June 30, 2016     Accepted: December 27, 2016     Published: January 17, 2017

ABSTRACT

We retrospectively analyzed LMR at diagnosis and at completion of first-line therapy and prognosis in173 patients with DLBCL from 2005 to 2016. We found that patients with an LMR < 3.2 at diagnosis, as well as at completion of first-line therapy, had significantly lower PFS and OS rates than those with an LMR ≥ 3.2 (P<0.05). Patients with LMR that recovered from the low level at diagnosis showed superior overall survival (OS) (P=0.000) and progression-free survival (PFS) (P=0.001) compared with patients who failed to achieve a higher value at the completion of therapy. The multivariate analysis demonstrated that LMR values that did not increase upon completion of first-line therapy were an independent predictor for inferior OS (P=0.021) and PFS (P=0.046). In conclusion, LMR at diagnosis and at completion of first-line therapy is a simple biomarker to predict clinical outcomes in DLBCL. LMR recovery from low levels at diagnosis, irrespective of whether LMR reached the cutoff value, was associated with improved clinical outcomes.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14700